复发难治性急性淋巴细胞白血病的治疗进展：对新治疗方法的迫切呼吁正在得到回应！
Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!
作者信息
DuVall Adam S, Sheade Jori, Anderson Daniela, Yates Samuel J, Stock Wendy
机构信息
University of Chicago Biological Sciences Division, Department of Medicine, Section of Hematology Oncology, Chicago, IL.
University of Chicago Biological Sciences Division, Department of Medicine, Chicago, IL.
出版信息
JCO Oncol Pract. 2022 Jul;18(7):479-487. doi: 10.1200/OP.21.00843. Epub 2022 Apr 5.
The treatment of acute lymphoblastic leukemia (ALL) has dramatically changed over the past three decades. However, relapsed and/or refractory ALL still remains with a very low survival and high morbidity associated with its treatment. Here, we will review the outstanding progress that has been made in the treatment of relapsed and/or refractory ALL and discuss future directions and challenges that require further investigation.
在过去三十年中，急性淋巴细胞白血病（ALL）的治疗发生了巨大变化。然而，复发和/或难治性ALL的生存率仍然很低，并且其治疗伴有高发病率。在此，我们将回顾复发和/或难治性ALL治疗中取得的显著进展，并讨论需要进一步研究的未来方向和挑战。
Zotero 插件